Condition: Alzheimer Disease · Sponsor: University Hospital, Toulouse
A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.
This description comes directly from the study's public registry record.
Julien DELRIEU, MD-PH · 05 61 77 70 58 · delrieu.j@chu-toulouse.fr
Delphine Pennetier · pennetier.d@chu-toulouse.fr
Always discuss trial participation with your own doctor first.
| University Hospital of Toulouse | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07367815